Compare Citius Pharmaceuticals Inc (CTXR) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Raymond James Financial, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Raymond James Financial, Inc. trades at $158.28 (market cap $30.51B). The key difference: Raymond James Financial, Inc. is far larger — about 2240.1× Citius Pharmaceuticals Inc's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Raymond James Financial, Inc. for 75 Days on average.
| CTXR | RJF | |
|---|---|---|
Market Cap | $13.62M | $30.51B |
Volume | 132,438 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $1.82 | $181.18 |
52-Week Low | $0.48 | $140.89 |
Typical Hold Time | 17 Days | 75 Days |
Enterprise Value | $3.79M | $24.37B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
RJF trades at $158.28, up 0.63% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.14 exceeding expectations. Revenue grew to $13.84B in 2025, and net income margin stands at 15.37%. Recent news highlights executive leadership changes and a declared dividend of $0.54 per share payable in October 2026.
The outlook is mixed: analyst consensus is a 'Hold' with a $184 price target, implying potential upside, but technical indicators signal near-term caution. Key risks include rising expenses and market volatility, while growth drivers include wealth management expansion and investment banking recovery. The stock presents a balanced opportunity with solid fundamentals offset by technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
